Annovis Bio, Inc (NYSE:ANVS) stock is trending Tuesday. The company eelier announced new data from its Phase III Parkinson's study.

What Happened: The study showed improvements on the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) following treatment with buntanetap.

The findings demonstrated that the placebo group experienced cognitive deterioration throughout the study, whereas the treatment groups experienced no further deterioration.

In patients with mild dementia, cognition declined more rapidly in the placebo group than in those treated with 10mg buntanetap. Treatment with 20mg buntanetap led to significant cognitive improvements compared to the placebo group.

Also, motor function improved in Parkinson's patients with a diagnosis of over three years who had experienced measurable deficits. Lastly, Postural Instability and Gait Difficulty patients responded better to the treatment and improved more compared to Parkinson's patients.

ANVS Price Action: Annovis Bio stock is up 8.16% at $5.70, according to Benzinga Pro.

Image: Unsplash/ Volodymyr Hryshchenko